Pfizer's earnings growth trade at a deep discount, suddenly a buy

Key PointsThe rotation into defensive names is here, and the healthcare stocks seem to be accumulating the bulk of employment and business activity.Pfizer offers above-average growth at a massive discount to competitors within that sector, like Eli Lilly and AstraZeneca.Analysts see the writing on the wall and aren't afraid to tell you about their price targets.5 stocks we like better than PfizerThe defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflo ...